Novo Nordisk A/S
A Development Scientist in the CMC Development team at Novo Nordisk applies advanced organic synthesis and peptide-protein modification expertise to create robust chemical processes for active pharmaceutical ingredients (APIs). The role involves scaling these processes from non-clinical development through Phase 2 clinical trials to support the manufacture of innovative therapies.
Headquarters
Alle, Central Jutland, Denmark
Company Size
10001+ employees
Founded
1923
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, with the stated purpose of driving change to defeat diabetes and other serious chronic diseases. It researches, develops, manufactures and markets pharmaceutical products and medical devices across diabetes care, obesity, haemophilia, growth disorders and other endocrine conditions, and is widely known for its insulin and GLP‑1 therapies. Combining extensive R&D, large‑scale manufacturing and global commercial reach, Novo Nordisk emphasizes patient‑centred care, access programs and sustainability in its work to improve outcomes for people with chronic disease.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Novo Nordisk A/S.
159% above the average for this role
Research Assistant (Organic Synthesis)
Nanyang Technological University
Synthetic Organic Chemist
Pfizer
Internal Applicants -Research Associate in Synthetic Organic Chemistry
UK Centre for Ecology and Hydrology
Senior Director, API Development
8a7882525b6027b0015b692822e001ab
Senior Scientist Synthetic Chemist In Oligonucleotide Therapeutics M%C3%B6lndal Sweden
AstraZeneca
Chemical Researcher - Peptide Synthesis
TAPI